Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Gains from Sales and Divestitures (2024 - 2025)

Xilio Therapeutics' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $111375.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 1882.82% year-over-year to $111375.0; the TTM value through Sep 2025 reached $111375.0, up 1882.82%, while the annual FY2024 figure was $5617.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $111375.0 at Xilio Therapeutics, roughly flat from $111375.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $111375.0 in Q1 2025 and bottomed at $4777.0 in Q1 2024.